Breast Cancer Research and Treatment **59**: 289-290, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 59

Aittomäki K 101
Andrews HN 199
Arencibia JM 255
Ashley S 171
Ashok S 163

Bacchi M 279
Baldetorp B 69
Barratt A 101
Bastert G 271
Batra S 163
Bengala C 133
Bernhard J 279
Bharaj B 153
Biganzoli E 211
Black MH 1
Blais DE 231
Bonnefoi H 279
Boracchi P 211
Bornstein BA 49
Bove L 223
Bruynseels J 55
Butow P 101

Carnino F 133
Castiglione M 279
Chadderton A 231
Chang JC 171
Chen X 81
Chew K 113
Connolly JL 49
Conte P 133
Crump M 55

D'Attino RM 223
D'Ottavio AM 223
Daniels IR 77
De Coster R 55
De Marco S 223
Del Mastro L 133
Dennert G 81
Deo S 163
Diamandis EP 1,153,263
Diel IJ 271
Dittadi R 211
Dowsett M 171

Emerman JT 199

Fabi A 223
Fernandez PM 15
Fernö M 69
Ferraresi V 223
Friedlander M 101
Fukushima P 27

Gaff C 101
Gallo L 133
Gannon BR 231
Garufi C 223
Gatti C 211
Gelman R 49
Giai M 153
Gion M 211
Gluck S 231
Goel R 55
Goldhirsch A 279
Gollan C 271
Goodson WH III 113
Goss PE 55
Grass L 263
Gregory RK 171
Groot K 255

Haan E 101
Halmos G 255
Hamann T 185
Harris JR 49
Hatschek T 69
Herrmann R 279
Hetelekidis S 49
Hiscox S 245
Hung G 81
Hürny C 279
Husain SA 163

Izzo F 223

Jacobs LK 15
Jiang WG 245

Kahán Z 255
Källström A-C 69

Kasumi F 177
Kennedy KA 15
Kerr LR 199
Kirk J 101
Kirwan-Rhude AF 231
Kurt RA 41

Lee AS 81
Lionetto R 133
Ljung B-M 113

Magklara A 263
Makita M 177
Malmström P 69
Manning FCR 15
Mansel R 245
Marsella A 223
Matsumoto K 245
Mayall B 113
Meiser B 101
Meo S 211
Meyberg GC 271
Michelotti A 133
Milella M 223
Miller FR 27
Montanaro E 133
Moore DH II 113

Nabholtz J-M 55
Nagy A 255
Nakamura T 245
Nisticò C 223
Nixon AJ 49
Nordenskjöld B 69

Ouatas T 27
Oza A 55

Paccagnella A 211
Pace A 223
Parissenti AM 231
Parr C 245
Patierno SR 15
Peiro G 49
Peloso L 211
Perey L 279

Powles TJ 171

Querci della Rovere G 77

Raina V 163
Ray G 163
Recht A 49
Reid C 55
Rosabian A 211
Rosso R 133
Rydén S 69

Sabbioni MEE 279
Saito M 177
Salter J 171
Schally AV 255
Schnitt SJ 49
Schoof DD 41
Schwartz AM 15
Shukla NK 163
Siegrist HP 279
Silver B 49
Sinn H-P 185
Smith HS 113
Solomayer E-F 271
Stål O 69
Steeg PS 27
Sterns EE 125
Stetler-Stevenson M 27
Strange KS 199

Tabbara SO 15
Tada T 177
Takahashi K 177
Terzoli E 223
Thürlimann B 279
Tibaldi C 133
Tropea F 223
Tsangaris TN 15
Tsuge T 141
Tsukamoto M 141
Tucker K 101
Tye LM 55
Uchida Y 177
Urba WJ 41

Vaccaro A 223
Vassilikos EJK 153
Venturini M 133
Villeneuve DJ 231
Vinante O 211

Wadden N 55
Waldman FM 113
Weinberg J 199
Wulfkuhle J 27

Yamakawa M 141
Yoshimoto M 177
Yu H 153

Zee B 125
Zhang D 81
Zhou Q 27

Breast Cancer Research and Treatment **59**: 291-293, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 59

adjuvant therapy
5 vs. 2 years tamoxifen beneficial for ER+/PgR+ but not ER+/PgR– breast cancer 69-76
erbB-2 as a predictor of response 171-175
anchorage-independent growth
stimulated preferentially by cyclin D1 transfection into MCF10A cells 27-39
androgen receptor
and differential steroid regulation of PSA, human glandular kallikrein 263-270
shorter CAG repeats in more aggressive breast cancer 153-161
antioxidant status
and free radical production, lipid peroxidation, in breast cancer 163-170
and the prognostic implication of TPA, cytokeratin fragments 211-221
drug-induced — resistance caused by induce GRP78 15-26
P-glycoprotein inhibitor restores Taxol sensitivity of apoptosis in drug resistant MCF-7 231-244
aromatase inhibitors
liarozole phase II trial — retinoid-type toxicities 55-68
axillary anatomy
variations — a case of "Axillary Arch of Langer" 77-80

bone metastasis
better prognosis than visceral site of first metastasis 271-278
BRCA1
age, tumor properties, and survival in hereditary breast cancer with and without BRCA1 mutation 185-192
breast cancer associated gene 1 (bcg-1)
tissue specificity of new gene found by subtractive hybridization in breast tumors 41-48
bromodeoxyuridine (BrdU)
vs. Ki-67 proliferation index in prognosis 113-123

c-met receptor
HGF/SF variant NK4 inhibits HGF/SF-induced phosphorylation, invasion 245-254
catalase
and antioxidant status, free radical production, in breast cancer 163-170
cellular immunity
association of NK cell count, β_2-microglobulin, and sIL-2r with good prognostic factors 279-287
chemoresponse prediction
see predictive factors
chemotherapy
active cytotoxic LH-RH conjugate in MDA-MB-231 xenografts 255-262
activity and cardiotoxicity of single agent epirubicin in first line 133-139
weekly vinorelbine with G-CSF support 223-229
conservative surgery
lobular carcinoma outcomes similar to ductal 49-54
cyclin D1
transfection into MCF10A cells stimulates only anchorage-independent growth 27-39
cytokeratin fragments
and tissue polypeptide antigen (TPA) in prognosis 211-221
cytokines
in breast tumors, and types of infiltrating and adjacent dendritic cells 141-152
cytotoxic conjugates
activity of 2-pyrrolinodoxorubicin linked to LH-RH on MDA-MB-231 xenografts 255-262

dendritic cells
distinct types in and around tumor nests, and tumor cytokine expression 141-152
drug resistance
association with GRP78 overexpression and resistance to apoptosis 15-26
P-glycoprotein inhibitor restores Taxol sensitivity of apoptosis in resistant MCF-7 231-244

endocrine therapy
5 vs. 2 years adjuvant tamoxifen beneficial for ER+/Pgr+ but not ER+/PgR– breast cancer 69-76
liarozole (aromatase inhibitor and retinomimetic) phase II trial 55-68
epirubicin
activity and cardiotoxicity as single agent in first line 133-139

erbB-2
predicting response and survival with neoadjuvant vs. adjuvant chemoendocrine therapy 171-175

familial breast cancer
age, tumor properties, and survival in hereditary breast cancer with and without BRCA1 mutation 185-192
characteristics affecting mammography compliance in high risk women 101-111
free radical production
and antioxidant status, lipid peroxidation, in breast cancer 163-170

G-CSF
with weekly dose-intense vinorelbine 223-229
gene therapy
eradication of mouse mammary cancer using GRP78 promoter with HSVtk 81-90
genes in breast cancer
new and known genes identified by subtractive hybridization of fresh specimens 41-48
glucose-regulated stress protein GRP78
directing HSVtk suicide gene therapy 81-90
overexpression in malignant but not benign breast lesions 15-26
glutathione peroxidase
and antioxidant status, free radical production, in breast cancer 163-170

heat shock proteins
and SC115 tumor growth in mice — effects of social housing condition 199-209
hepatectomy
in treatment of liver metastases 177-184
hepatocyte growth factor / scatter factor (HGF/SF)
variant NK4 inhibits HGF/SF-induced invasion 245-254
HER-2/*neu*
see erbB-2
hereditary breast cancer
see familial breast cancer
high risk women
characteristics affecting mammography compliance 101-111
hormone replacement therapy (HRT)
prevents post-menopausal decrease in mammographic density 125-132
HSVtk suicide gene therapy
eradication of mouse mammary cancer using GRP78 promoter 81-90

immune memory
induced by HSVtk under GRP78 promoter 81-90
immune response
cytokines in tumors, and types of infiltrating and adjacent dendritic cells 141-152
immune status
association of NK cell count, β_2-microglobulin, and sIL-2r with good prognostic factors 279-287

kallikreins
and activation of PSA 1-14
PSA and human glandular kallikrein — differential steroid regulation in breast cancer cells 263-270
Ki-67
vs. BrdU proliferation index in prognosis 113-123

liarozole
phase II trial — aromatase inhibitor and retinomimetic activities and toxicities 55-68
lipid peroxidation
and antioxidant status, free radical production, in breast cancer 163-170
liver metastasis
benefit of surgical treatment 177-184
lobular carcinoma
same outcomes as ductal with conservative surgery and radiation 49-54
luteinizing hormone-releasing hormone receptors
target for active cytotoxic LH-RH conjugate in MDA-MB-231 xenografts 255-262

malondialdehyde
and antioxidant status, free radical production, in breast cancer 163-170
mammographic density
decrease after menopause prevented by HRT 125-132
mammography
characteristics affecting compliance in high risk women 101-111
MCF10A human breast cells
cyclin D1 transfection stimulates only anchorage-independent growth 27-39
metastasis
bone vs. visceral site of first metastasis, and prognosis 271-278
HGF/SF variant NK4 inhibits HGF/SF-induced invasion 245-254

neoadjuvant therapy
erbB-2 as a predictor of response 171-175

P-glycoprotein
inhibition restores paclitaxel sensitivity in resistant MCF-7 cells 231-244
paclitaxel
induction of apoptosis restored by P-glycoprotein inhibitor in resistant MCF-7 cells 231-244
predictive factors
erbB-2 in predicting response to neoadjuvant chemoendocrine therapy 171-175
premalignant disease progression
cyclin D1 transfection into MCF10A cells stimulates only anchorage-independent growth 27-39
progesterone receptor
5 vs. 2 years adjuvant tamoxifen beneficial for ER+/Pgr+ but not ER+/PgR– breast cancer 69-76
prognostic factors
association of NK cell count, β_2-microglobulin, sIL-2r with good prognostic factors 279-287
bone vs. visceral site of first metastasis 271-278
BrdU vs. Ki-67 proliferation measures 113-123
erbB-2 in DFS with neoadjuvant vs. adjuvant chemoendocrine therapy 171 175
prostate-specific antigen (PSA) in breast disease — review 1-14
shorter CAG repeats in androgen receptor gene and more aggressive breast cancer 153-161
tissue polypeptide antigen (TPA) and cytokeratin fragments 211-221
proliferation rate
prognostic value of BrdU vs. Ki-67 113-123
prostate-specific antigen (PSA)
and human glandular kallikrein — differential steroid regulation in breast cancer cells 263-270
review — diagnostic and prognostic use in breast disease 1-14
psychosocial stressors
stress response proteins and SC115 tumor growth in mice with different social housing conditions 199-209

radiation therapy
lobular carcinoma outcomes similar to ductal 49-54
reactive oxygen metabolites
and antioxidant status, free radical production, in breast cancer 163-170

screening
characteristics affecting attendance in high risk women 101-111
serum markers
prostate-specific antigen (PSA) in breast disease — review 1-14
Shionogi mouse mammary carcinoma (SC115)
stress response proteins and tumor growth in mice with different social housing conditions 199-209
stress response proteins
and SC115 tumor growth in mice — effects of social housing condition 199-209
GRP78 overexpression in malignant but not benign breast lesions 15-26
subtractive hybridization
genes overexpressed in breast cancer specimens 41-48
superoxide dismutase
and antioxidant status, free radical production, in breast cancer 163-170
surgery
axillary variations — a case of "Axillary Arch of Langer" 77-80
benefit of hepatectomy for liver metastases 177-184

tamoxifen
5 vs. 2 years beneficial for ER+/Pgr+ but not ER+/PgR– breast cancer 69-76
tissue polypeptide antigen (TPA)
and cytokeratin fragments in prognosis 211-221

vinorelbine
weekly schedule with G-CSF support 223-229
visceral metastasis
poorer prognosis than bone site of first metastasis 271-278